Followers | 241 |
Posts | 3530 |
Boards Moderated | 0 |
Alias Born | 05/01/2010 |
Thursday, July 15, 2010 4:12:45 PM
There are many more things to look into than efficacy. I like Lorcaserin's side effects profile. I also like how the drug works.
People simply do not understand the differences in the two drugs; Lorcaserin vs. Qnexa.... VERY DIFFERENT mechanisms of action.
If VVUS gets the boot because more data is needed, etc. then game is on for ARNA. This leaves ARNA in the spotlight for 2010 as THE OBESITY DRUG CANDIDATE.
If VVUS had an approval, then money left ARNA to join the bandwagon. If this is the case, the market is large enough for both Qnexa and Lorcaserin.
The game is not over for ARNA.
Here's a previous post that I wrote on how to trade ARNA in July:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=51287926
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM